Monte Rosa CSO exercises options, sells 6K shares

Monte Rosa Therapeutics Chief Scientific Officer Sharon Townson reported an exercise-and-sell transaction in company stock.

Rhea-AI Filing Summary

Monte Rosa Therapeutics Chief Scientific Officer Sharon Townson reported an exercise-and-sell transaction in company stock. On July 6, 2026, she exercised options to acquire 6,000 shares of common stock at $6.14 per share and sold a total of 6,000 shares in open-market trades, including 400 shares at $24.13 and additional shares at a weighted average price of $23.2495 within a range of $22.97 to $23.65. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan. After the trades, she directly holds 67,845 shares of common stock.

Insider Trade Summary 10b5-1

Exercise and Sale: 6,000 shares ($103K approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Townson Sharon

Role Chief Scientific Officer

Sold 6,000 shs ($140K)

Approx. gross sale proceeds $140K

Approx. exercise cost $37K

Approx. pre-tax spread $103K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	6,000	$0.00	$0.00
Exercise	Common Stock	6,000	$6.14	$37K
Sale	Common Stock	5,600	$23.2495	$130K
Sale	Common Stock	400	$24.13	$10K

Holdings After Transaction: Stock Option (Right to Buy) — 197,290 contracts (Direct); Common Stock — 67,845 shares (Direct)

Footnotes (3)

1. F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.97 to $23.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
3. F3. The shares underlying this option are fully vested and exercisable.

Key Figures

Shares sold: 6,000 shares Sale price (block 1): $24.13 per share Sale price (block 2 avg.): $23.2495 per share +3 more

6 metrics

Shares sold 6,000 shares Total common stock sold on July 6, 2026

Sale price (block 1) $24.13 per share 400-share open-market sale

Sale price (block 2 avg.) $23.2495 per share Weighted average for additional sales, range $22.97–$23.65

Options exercised 6,000 shares Common stock acquired via option exercise

Option exercise price $6.14 per share Strike price for stock option exercised

Shares held after 67,845 shares Direct common stock ownership following transactions

Key Terms

Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), Exercise or conversion of derivative security, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Exercise or conversion of derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Monte Rosa Therapeutics (GLUE) CSO Sharon Townson do in this Form 4?

Sharon Townson reported exercising options for 6,000 Monte Rosa Therapeutics shares and selling 6,000 shares in open-market transactions. The activity reflects an exercise-and-sell pattern disclosed in a regulatory filing.

How many Monte Rosa Therapeutics (GLUE) shares did Sharon Townson sell?

She sold a total of 6,000 common shares. This included 400 shares at $24.13 per share and additional shares at a weighted average price of $23.2495, within a range of $22.97 to $23.65.

At what price did Sharon Townson exercise options for Monte Rosa Therapeutics (GLUE) stock?

She exercised stock options to acquire 6,000 Monte Rosa Therapeutics common shares at $6.14 per share. This option exercise converted derivative rights into actual shares before subsequent open-market sales on the same date.

How many Monte Rosa Therapeutics (GLUE) shares does Sharon Townson hold after these transactions?

Following the reported transactions, Sharon Townson directly holds 67,845 shares of Monte Rosa Therapeutics common stock. This post-transaction balance reflects her remaining equity stake after the option exercise and share sales.

Were Sharon Townson’s Monte Rosa Therapeutics (GLUE) trades under a Rule 10b5-1 plan?

Yes, the filing states these transactions were executed under a Rule 10b5-1 trading plan adopted on February 27, 2026. Such plans pre-schedule trades, indicating the timing was established in advance.

What type of insider transactions are reported for Monte Rosa Therapeutics (GLUE) in this Form 4?

The Form 4 reports an option exercise and open-market sales of common stock. One transaction reflects exercising a stock option, while two separate entries show sales of the resulting shares at market prices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/07/2026 - 04:41 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Townson Sharon

(Last) (First) (Middle)

MONTE ROSA THERAPEUTICS, INC.

321 HARRISON AVENUE, SUITE 900

(Street)

BOSTON MASSACHUSETTS 02118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Monte Rosa Therapeutics, Inc. [ GLUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/06/2026		M(1)		6,000	A	$6.14	73,845	D
Common Stock	07/06/2026		S(1)		5,600	D	$23.2495(2)	68,245	D
Common Stock	07/06/2026		S(1)		400	D	$24.13	67,845	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.14	07/06/2026		M(1)			6,000	(3)	04/12/2031	Common Stock	6,000	$0	197,290	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.97 to $23.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. The shares underlying this option are fully vested and exercisable.

	/s/ Phil Nickson, Attorney-in-Fact	07/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)